Navigation Links
The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher
Date:9/30/2008

LLS Specialized Center of Research Program Hits $178 Million Mark

WHITE PLAINS, N.Y., Sept. 30 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded a new Marshall A. Lichtman Specialized Center of Research (SCOR) grant to Beverly Mitchell, M.D., George E. Becker Professor of Medicine at Stanford University.

Dr. Mitchell and her team will receive $1.25 million a year for five years, for a total of $6.25 million. The SCOR program is LLS's largest research grant, with total funding of $178.25 million since its inception in 2000. The title of her SCOR is: Molecular and Cellular Characterization of Myelodysplastic Syndromes.

The SCOR program brings together teams of researchers representing different disciplines in collaborative efforts to discover new approaches to treat patients with leukemia, lymphoma and myeloma. Awards go to groups that best demonstrate outstanding scientific promise facilitated by the synergy that will occur from their combined efforts.

Dr. Mitchell's team is studying stem cells in myelodysplastic syndromes (MDS), a collection of related disorders in which damaged bone marrow cells can't mature into functional blood cells. The disorders frequently progress to acute myelogenous leukemia (AML). Her team has recently identified new molecular markers than can help identify the MDS stem cells that have progressed to AML, and are working to develop therapies to target these abnormal MDS stem cells. A clinical trial of an investigational drug that targets one of the enzymes involved in the development of MDS will be initiated.

"Dr. Mitchell and her team of investigators are undertaking cutting-edge research to reach a better understanding of the root causes of MDS," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "Their work will likely lead to new therapies that target these diseases. This research team is an impressive addition to the outstanding scientists already in the SCOR program."

SCOR is one of three integrated research grant programs established by LLS. These also include the Career Development Program, which provides stipends to investigators of exceptional promise in the early stages of their careers; and the Translational Research Program, which encourages and supports outstanding research with strong promise of translating emerging biomedical knowledge into new treatments. In addition, the Therapy Acceleration Program is designed to help move potential therapies more quickly through the development pipeline.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 6.3 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call LLS's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Andrea Greif

914-821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New leukemia signal could point way to better treatment, Stanford researchers find
2. The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years
3. Stater Bros. Raises $200,000 for the Leukemia & Lymphoma Society
4. Methadone Kills Resistant Leukemia Cells
5. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
6. Leukemia drug could save lives of stroke patients
7. Math could help cure leukemia
8. Gene mutation improves leukemia drugs effect
9. Microenvironment a main driver of aggressive multi-lineage leukemia disease type
10. Clinical study shows biological and clinical activity in relapsed leukemia patients
11. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... FL (PRWEB) , ... September 21, 2017 , ... 38-Year-Old ... Aesthetic Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet ... Top 40 Under 40 is an annual award that was started in ...
(Date:9/21/2017)... Chicago, IL (PRWEB) , ... September 21, 2017 , ... ... set to run from September 11 to the end of November. , The Chicago, ... out to their community and teach them about the ease of taking their personal ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing ... in compliance with FDA rules. , The FDA has issued two draft guidances ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and ... departments have been awarded five-year accreditation status through the Public Health Accreditation ... served by a PHAB-accredited health department now extend to more than 203 ...
(Date:9/21/2017)... ... 21, 2017 , ... In addition to sticking with the ... holistic approach and use natural alternatives for all house cleaning products, disinfectants, respiratory ... guaranteeing that, the new line of essential oils, are all 100% organic and ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017 Dealmed Medical Supplies, New ... equipment, supplies, drugs, vaccines, and specialty medical products and ... agreement to acquire Vantage Medical Supplies, a major distributor ... Holtsville, New York . ... emerging medical practices, will operate under the Dealmed name ...
(Date:9/7/2017)... Sept. 7, 2017  For nearly two decades, New Life Agency has ... Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way partnership ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... 7, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... announced that it will be participating in the Morgan ... the Grand Hyatt hotel in New York.  Zimmer Biomet ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .   ...
Breaking Medicine Technology: